Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

Dow Jones

Jun 17

0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company "looks like it could continue to deliver mid-teen EPS growth." (mike.cherney@wsj.com)

(END) Dow Jones Newswires

June 16, 2025 22:15 ET (02:15 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2544360933"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544360933\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544360933?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-17 10:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544360933","market":"other","top_or_hot":-1,"title":"Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company \"looks like it could continue to deliver mid-teen EPS growth.\" (mike.cherney@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2025 22:15 ET (02:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHigher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-17 10:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company \"looks like it could continue to deliver mid-teen EPS growth.\" (mike.cherney@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 16, 2025 22:15 ET (02:15 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CSL","symbol_name":"卡莱尔伙伴","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2544360933","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544360933","pubTimestamp":1750126500,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company \"looks like it could continue to deliver mid-teen EPS growth.\" ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CSL":"卡莱尔伙伴","CSL.AU":"CSL LIMITED"},"translate_title":"CSL的Andembry提供更高的利润率将提高盈利——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":0.9,"CSL":1},"content_text":"0215 GMT - Andembry, a new treatment for hereditary angioedema from Australia-based CSL, will offer a 20% margin uplift compared with CSL's existing treatment for the condition, say Jefferies analysts David Stanton and Vanessa Thomson. Although Andembry will likely cannibalize sales of the existing treatment, Haegarda, the Jefferies analysts still expect an earnings uplift of US$49 million in FY 2026 from the new product. Andembry was just approved by U.S. health authorities, building on other recent approvals of the treatment in Australia, Europe, Japan and elsewhere. The Jefferies analysts keep a bullish call on CSL, saying the company \"looks like it could continue to deliver mid-teen EPS growth.\" (mike.cherney@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 16, 2025 22:15 ET (02:15 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}